Technetium Tc-99m ciprofloxacin

Identification

Name
Technetium Tc-99m ciprofloxacin
Accession Number
DB05488
Type
Small Molecule
Groups
Investigational
Description

99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis, wound infection, abdominal abscess, pneumonia, appendicitis and tuberculosis. INFECTON combines the widely used antibiotic, ciprofloxacin, with Technetium ((99m)Tc), the most commonly used radioisotope in nuclear medical imaging There is currently controversy around the drug's ability to discriminate between sterile inflammation and bacterial versus nonbacterial infections.

Synonyms
  • 99mTc-ciprofloxacin
  • Infecton
  • Technetium (99mTc) ciprofloxacin
  • Technetium Tc 99m ciprofloxacin
Categories
UNII
Not Available
CAS number
374107-43-4
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in infectious and parasitic disease (unspecified).

Pharmacodynamics

This radiopharmaceutical diagnostic imaging agent is being investigated for its ability to uniquely detect and determine the location of bacterial infection in patients with difficult-to-diagnose signs and symptoms. This may be of use with the potential diagnosis of infection, including fever of unknown origin, osteomyelitis, wound infection, abdominal abscess, pneumonia, appendicitis and tuberculosis.

Mechanism of action

Ciprofloxacin is a fluoroquinolone antibiotic. The mechanism of action of these fluoroquinolones is not fully understood, but it has been postulated that the interaction of ciprofloxacin with bacterial DNA gyrase (a type II topoisomerase) prevents DNA uncoiling and subsequent DNA synthesis within bacteria. Ciprofloxacin demonstrates a significant antibiotic effect for both gram-negative and gram-positive bacteria in either stationary or growth phases of bacterial replication. However, the addition of the 99mTc atom likely affects the interaction of the ciprofloxacin molecule with the enzyme.

TargetActionsOrganism
UDNA gyrase subunit BNot AvailableEscherichia coli (strain K12)
UDNA topoisomerase 2-betaNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Technetium Tc-99m ciprofloxacin.
(S)-WarfarinThe therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Technetium Tc-99m ciprofloxacin.
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Technetium Tc-99m ciprofloxacin.
3-isobutyl-1-methyl-7H-xanthineThe serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Technetium Tc-99m ciprofloxacin.
4-hydroxycoumarinThe therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Technetium Tc-99m ciprofloxacin.
6-O-benzylguanineThe serum concentration of 6-O-benzylguanine can be increased when it is combined with Technetium Tc-99m ciprofloxacin.
7-DeazaguanineThe serum concentration of 7-Deazaguanine can be increased when it is combined with Technetium Tc-99m ciprofloxacin.
7,9-DimethylguanineThe serum concentration of 7,9-Dimethylguanine can be increased when it is combined with Technetium Tc-99m ciprofloxacin.
8-azaguanineThe serum concentration of 8-azaguanine can be increased when it is combined with Technetium Tc-99m ciprofloxacin.
8-chlorotheophyllineThe serum concentration of 8-chlorotheophylline can be increased when it is combined with Technetium Tc-99m ciprofloxacin.
Food Interactions
Not Available

References

General References
  1. Choe YM, Choe W, Lee KY, Ahn SI, Kim K, Cho YU, Choi SK, Hur YS, Kim SJ, Hong KC, Shin SH, Kim KR, Woo ZH: Tc-99m ciprofloxacin imaging in acute cholecystitis. World J Gastroenterol. 2007 Jun 21;13(23):3249-52. [PubMed:17589906]
  2. Markou P, Spyridonidis T: [The role of 99mTc-ciprofloxacin scan in infection imaging]. Hell J Nucl Med. 2005 May-Aug;8(2):74-80. [PubMed:16142247]
  3. Tossing G: 99mTc-ciprofloxacin DRAXIMAGE. IDrugs. 2004 Apr;7(4):374-9. [PubMed:15057643]
External Links
PubChem Substance
175427018

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Magnesium ion binding
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrB
Uniprot ID
P0AES6
Uniprot Name
DNA gyrase subunit B
Molecular Weight
89949.195 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein kinase c binding
Specific Function
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks.
Gene Name
TOP2B
Uniprot ID
Q02880
Uniprot Name
DNA topoisomerase 2-beta
Molecular Weight
183265.825 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Batty KT, Davis TM, Ilett KF, Dusci LJ, Langton SR: The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 1995 Mar;39(3):305-11. [PubMed:7619673]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  4. Drug Interactions & Labeling - FDA [Link]

Drug created on November 18, 2007 11:25 / Updated on November 02, 2018 06:10